“Narendra Solanki is constructive on the healthcare sector, particularly hospitals, and anticipates a gradual turnaround in pharma manufacturing. He identifies upcoming GLP-1 patent expiries in early 2026 in major markets like India and Brazil, alongside opportunities in complex generics, as key catalysts for the sector.”

Narendra Solanki’s track record: 9 graded calls · 95% CI 6–55%